BMJ2d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ11d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ11d
Vascular occlusion for optimising the functional improvement in patients with knee osteoarthritis: a randomised controlled trial
Objectives Knee osteoarthritis (KOA) is a leading cause of global disability with conventional exercise yielding only modest improvements. Here we aimed to investigate the benefits of integrating ...
BMJ13d
Evidence that autoantibody production may be driven by acute Epstein-Barr virus infection in Sjögren’s disease
Objectives Sjögren’s disease (SD) is an autoimmune disease affecting the exocrine glands that is associated with autoantibodies against Ro60/SS-A, anti-Ro52/TRIM21, La/SS-B and others. We examined the ...
BMJ19d
Treatment of early oligoarticular psoriatic arthritis with apremilast: primary outcomes at week 16 from the FOREMOST randomised controlled trial
Objectives Oligoarticular psoriatic arthritis (PsA) is frequent but rarely studied. The objective was to assess the efficacy of apremilast in early oligoarticular PsA. Methods FOREMOST (NCT03747939) ...
BMJ19d
Stratification according to autoantibody status in systemic sclerosis reveals distinct molecular signatures
Objectives Systemic sclerosis (SSc) is a heterogeneous disease, complicating its management. Its complexity and the insufficiency of clinical manifestations alone to delineate homogeneous patient ...
BMJ24d
Microbiome research in autoimmune and immune-mediated inflammatory diseases: lessons, advances and unmet needs
The increasing prevalence of autoimmune and immune-mediated diseases (AIMDs) underscores the need to understand environmental factors that contribute to their pathogenesis, with the microbiome ...
BMJ26d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis
Objective To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods Patients with vasculitis or comparator diseases were recruited into an ...
BMJ29d
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Objectives To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods An ...
BMJ1mon
Meta-analysis of erosive hand osteoarthritis identifies four common variants that associate with relatively large effect
Correspondence to Dr Unnur Styrkarsdottir, Population Genomics, deCODE genetics / Amgen Inc, Reykjavik, Iceland; unnur.styrkarsdottir{at}decode.is; Kari Stefansson ...
BMJ1mon
Protection against tuberculosis: cytokines, T cells, and macrophages
Correspondence: Professor S H E Kaufmann, Max-Planck-Institute for Infection Biology, Department of Immunology, Schumannstrasse 21-22, D-10117 Berlin, Germany; kaufmann{at}mpiib-berlin.mpg.de ...
BMJ1mon
Single-cell analysis reveals key differences between early-stage and late-stage systemic sclerosis skin across autoantibody subgroups
Objectives The severity of skin involvement in diffuse cutaneous systemic sclerosis (dcSSc) depends on stage of disease and differs between anti-RNA-polymerase III (ARA) and anti-topoisomerase ...